Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Call of the Day: Eli Lilly getting a price target boost at Jefferies
01:15pm, Tuesday, 13'th Feb 2024
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to to discuss the latest raise to Eli Lilly.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:06am, Tuesday, 13'th Feb 2024
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly partner BioAge raises $170 mln for obesity treatment
09:17am, Tuesday, 13'th Feb 2024
BioAge Labs, a biotech startup collaborating with Eli Lilly for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
05:50am, Tuesday, 13'th Feb 2024
Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.
A Look at Pharma ETFs After Q4 Earnings
02:01pm, Monday, 12'th Feb 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re
This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?
08:45am, Monday, 12'th Feb 2024
Eli Lilly's tirzepatide reported positive phase 2 results in treating a severe disease. The drugmaker may well ride the wave of tirzepatide's successes for a long time.
Short sellers boosted by ‘Hedge Fund Nirvana' that sees most heavily-shorted companies suffer
07:47am, Monday, 12'th Feb 2024
Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
05:03am, Monday, 12'th Feb 2024
Eli Lilly's weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030, Goldman Sach
Lilly Pulitzer CEO talks cost pressures, innovation, new products areas including home and athletic
04:00pm, Saturday, 10'th Feb 2024
The most recent University of Michigan Consumer Sentiment Index reading showed a climb in consumer sentiment despite dealing with sticky inflation (prices have not adjusted as quickly to supply and de
Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?
11:30am, Saturday, 10'th Feb 2024
A clinical trial for one of Eli Lilly's gene therapy candidates for hearing loss just reported good data. Even if it gets approved eventually, it might not make much money.
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
08:00am, Saturday, 10'th Feb 2024
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
Why Shares of Eli Lilly Popped This Week
02:34pm, Friday, 09'th Feb 2024
Eli Lilly just reported strong Q4 earnings. The stock is soaring due to the growth of its weight loss drugs.
3 Stocks to Sell Immediately Before the Bubble Bursts: February 2024
12:20pm, Friday, 09'th Feb 2024
The Federal Reserve appears set to start cutting interest rates in the coming months. That has set the bulls loose on Wall Street as traders rush to profit from the forthcoming easing in monetary poli
Is Eli Lilly Stock a Buy Now?
07:15am, Friday, 09'th Feb 2024
Diabetic medication Mounjaro is now Eli Lilly's top-selling drug. The company is projecting another year of 20% revenue growth in 2024.
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
04:56pm, Thursday, 08'th Feb 2024
Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.
